Vitro Biopharma, Inc. (VTRO)

Vitro Biopharma Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2021	Oct 31, 2020
Cash & Equivalents	2.22	4.38	0.3
Cash & Cash Equivalents	2.22	4.38	0.3
Cash Growth	-	1372.68%	-
Receivables	0.42	0.13	0.15
Inventory	-	0.12	0.04
Other Current Assets	1.11	0.01	0
Total Current Assets	3.74	4.64	0.48
Property, Plant & Equipment	-	0.12	0.15
Goodwill and Intangibles	-	6.37	0.39
Other Long-Term Assets	-	0	0
Total Long-Term Assets	-	6.49	0.54
Total Assets	-	11.13	1.03
Accounts Payable	-	0.06	0.08
Deferred Revenue	-	0.5	-
Current Debt	-	0.17	0.11
Other Current Liabilities	1.04	0.69	0.37
Total Current Liabilities	1.04	1.42	0.55
Long-Term Debt	-	6.14	3.1
Other Long-Term Liabilities	-	0.11	0
Total Long-Term Liabilities	-	6.25	3.1
Total Liabilities	-	7.67	3.65
Total Debt	3.01	6.31	3.2
Debt Growth	-	96.86%	-
Retained Earnings	-	-15.86	-11.34
Shareholders' Equity	6.35	3.45	-2.63
Net Cash / Debt	-0.79	-1.93	-2.91
Working Capital	2.71	3.21	-0.07

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).